Mounjaro Side Effects
Mounjaro (tirzepatide) is a once weekly injection approved for type 2 diabetes. This page explains the side effects named in its FDA approved prescribing information, in plain language: the reactions reported most often, when they tend to happen, and the serious warnings on the label. It is education only, not medical advice.
The most common Mounjaro side effects
Most of the reactions reported with Mounjaro involve the stomach, digestion and appetite, because the medicine slows stomach emptying and reduces hunger. The reactions named as most common in the prescribing information are:
- Nausea. The most frequently reported reaction, especially early in treatment and after increases.
- Diarrhea. Loose or frequent stools, reported most often while the dose is going up.
- Reduced appetite. Part of how the medicine works, and itself listed as a reaction.
- Vomiting. Often connected to dose increases or eating more than feels comfortable.
- Constipation. Slower digestion can mean less frequent, harder stools.
- Indigestion. Listed on the label as dyspepsia, a feeling of discomfort after eating.
- Stomach pain. Abdominal pain or discomfort.
Injection site reactions, such as redness or itching at the spot where the pen was used, are also listed on the label and are usually mild. Not everyone gets these effects, and the pattern and severity vary a lot from person to person.
When side effects tend to happen
The stomach related reactions are reported most often during dose escalation, when the dose is stepped up every four weeks. The Mounjaro dosage chart shows that climb, from the 2.5 mg starting dose upward in 2.5 mg steps. The starting dose exists mainly to let the body adjust, not to control blood sugar on its own. For many people, reactions that flare after an increase ease once the dose stays the same for a while. Side effects that are severe or not settling are a common reason a prescriber holds a dose for longer instead of stepping up on schedule.
Warnings in the Mounjaro prescribing information
Boxed warning: thyroid C-cell tumors. The strongest warning on the label is about a possible risk of thyroid C-cell tumors. In animal studies, tirzepatide caused these tumors in rats. It is not known whether Mounjaro causes them in people. The label says the medicine should not be used by people with a personal or family history of medullary thyroid carcinoma, or with a condition called multiple endocrine neoplasia syndrome type 2.
Pancreatitis. Inflammation of the pancreas has been reported with this class of medicine. The label describes severe stomach pain, sometimes spreading to the back, as the warning sign.
Gallbladder problems. Gallstones and gallbladder inflammation have been reported. Pain in the upper right stomach area, fever, or yellowing of the skin or eyes are the signs the label points to.
Severe stomach problems. Because Mounjaro slows stomach emptying, the label notes it has not been studied in people with severe gastroparesis and is generally not recommended for them.
Allergic reactions. Serious allergic reactions, including anaphylaxis and swelling of the face, lips or tongue, have been reported with tirzepatide medicines.
Low blood sugar with certain other medicines. Used on its own, Mounjaro is not expected to cause low blood sugar in most people. The label warns the risk rises when it is combined with insulin or a sulfonylurea.
When to get medical care promptly
Some symptoms should never be waited out. Seek medical care promptly for severe or persistent stomach pain, signs of an allergic reaction such as swelling of the face, lips or tongue or trouble breathing, yellowing of the skin or eyes, or a lump or swelling in the neck, a hoarse voice, or trouble swallowing. Ongoing vomiting or diarrhea that stops you drinking enough fluid also deserves a prompt call, because dehydration can strain the kidneys.
Frequently asked questions
What are the most common side effects of Mounjaro?
The reactions reported most often in the Mounjaro prescribing information are gastrointestinal: nausea, diarrhea, reduced appetite, vomiting, constipation, indigestion and stomach pain. Nearly all of the common list involves the stomach, digestion or appetite, which fits how the medicine works.
Do Mounjaro side effects settle down over time?
For many people, yes. The stomach related reactions are reported most often during dose escalation, while the dose is stepped up every four weeks. As the body adjusts to a steady dose, they often become milder or less frequent, although not for everyone, and severe or ongoing symptoms should always be raised with the prescriber.
Are injection site reactions a Mounjaro side effect?
Injection site reactions, such as redness or itching where the pen was used, are listed in the Mounjaro prescribing information and are usually mild. A reaction that spreads, is painful, or comes with swelling of the face or trouble breathing needs prompt medical care, as it can signal a serious allergic reaction instead.
What is the boxed warning on the Mounjaro label?
The boxed warning is about thyroid C-cell tumors. In studies, tirzepatide caused these tumors in rats. It is not known whether Mounjaro causes them in people. Because of this, the label says the medicine should not be used by people with a personal or family history of medullary thyroid carcinoma, or with multiple endocrine neoplasia syndrome type 2.
When should someone taking Mounjaro get medical care promptly?
The warnings on the label point to a few situations: severe or persistent stomach pain, which can be a sign of pancreatitis; signs of a serious allergic reaction such as swelling of the face, lips or tongue or trouble breathing; yellowing of the skin or eyes; and a lump or swelling in the neck, hoarseness or trouble swallowing.